[go: up one dir, main page]

PT3261625T - Formulações estimulantes de libertação de tripulso - Google Patents

Formulações estimulantes de libertação de tripulso

Info

Publication number
PT3261625T
PT3261625T PT167564855T PT16756485T PT3261625T PT 3261625 T PT3261625 T PT 3261625T PT 167564855 T PT167564855 T PT 167564855T PT 16756485 T PT16756485 T PT 16756485T PT 3261625 T PT3261625 T PT 3261625T
Authority
PT
Portugal
Prior art keywords
tripulse
release stimulant
formulations
stimulant formulations
release
Prior art date
Application number
PT167564855T
Other languages
English (en)
Original Assignee
Cingulate Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cingulate Therapeutics LLC filed Critical Cingulate Therapeutics LLC
Publication of PT3261625T publication Critical patent/PT3261625T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT167564855T 2015-02-27 2016-02-26 Formulações estimulantes de libertação de tripulso PT3261625T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562121537P 2015-02-27 2015-02-27

Publications (1)

Publication Number Publication Date
PT3261625T true PT3261625T (pt) 2024-11-18

Family

ID=56789928

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167564855T PT3261625T (pt) 2015-02-27 2016-02-26 Formulações estimulantes de libertação de tripulso

Country Status (22)

Country Link
US (5) US20160250148A1 (pt)
EP (1) EP3261625B1 (pt)
JP (2) JP2018506590A (pt)
KR (2) KR20170134409A (pt)
CN (1) CN107530289A (pt)
AU (2) AU2016225052B2 (pt)
BR (1) BR112017018322A2 (pt)
CA (1) CA2977540C (pt)
DK (1) DK3261625T3 (pt)
ES (1) ES2998038T3 (pt)
FI (1) FI3261625T3 (pt)
HR (1) HRP20241548T1 (pt)
HU (1) HUE068990T2 (pt)
IL (1) IL254159B2 (pt)
LT (1) LT3261625T (pt)
MX (1) MX2017011005A (pt)
PL (1) PL3261625T3 (pt)
PT (1) PT3261625T (pt)
RS (1) RS66154B1 (pt)
SI (1) SI3261625T1 (pt)
SM (1) SMT202400479T1 (pt)
WO (1) WO2016138440A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021197376A1 (zh) * 2020-03-31 2021-10-07 江苏恒瑞医药股份有限公司 一种非布司他片
JP2024518515A (ja) * 2021-05-11 2024-05-01 シンギュレイト・セラピューティクス・リミテッド・ライアビリティ・カンパニー トリモーダル高精度タイミングパルス型放出錠剤
CA3252172A1 (en) * 2022-02-16 2023-08-24 Cingulate Therapeutics LLC PRECISION-SYNCHRONIZED TRIMODAL TABLET

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131402A1 (de) 1981-08-07 1983-02-24 Kilian & Co GmbH, 5000 Köln Verfahren und tablettenpresse zum aufeinanderfolgenden herstellen einer vielzahl von tabletten mit gleichem gewicht
DE3404108A1 (de) 1984-02-07 1985-08-14 Kilian & Co GmbH, 5000 Köln Tablettenpresse
DE9306785U1 (de) 1993-05-05 1993-07-08 Kilian & Co. GmbH Maschinenfabrik, 5000 Köln Rundlauf-Tablettenpresse
ES2178078T3 (es) 1997-07-23 2002-12-16 Kilian Gmbh & Co Kg Prensa de comprimidos con marcha concentrica.
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6217904B1 (en) * 1999-04-06 2001-04-17 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
JP4316871B2 (ja) 2000-06-20 2009-08-19 株式会社三和化学研究所 核を有する成型品、その製造方法、及びその製造装置
WO2002000213A1 (en) * 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CA2461457C (en) 2001-09-26 2011-02-01 Sanwa Kagaku Kenkyusho Co., Ltd. Multi-core press-coated molded product, and method and apparatus for manufacturing the same
JP4248225B2 (ja) 2002-11-01 2009-04-02 トヨタ自動車株式会社 燃料電池システム
JP4693628B2 (ja) 2003-11-14 2011-06-01 株式会社三和化学研究所 有核成型品の製造方法
DK1782944T3 (da) 2004-08-26 2014-09-01 Kikusui Seisakusho Ltd Maskine til formning med rotationskompression, som anvender et stempel
DE202005001556U1 (de) 2005-01-31 2006-03-16 Kilian Gmbh & Co. Kg Matritzenscheibe für Rundlauf-Tablettepresse und Rundlauf-Tablettenpresse
MX2008014455A (es) * 2006-05-12 2008-11-27 Shire Llc Sistema de suministro de farmaco de dosis controlada.
DE202007002707U1 (de) 2007-02-21 2008-07-03 Ima Kilian Gmbh & Co.Kg Füllschuh für Rotationstablettenpressen
US20100104621A1 (en) * 2007-02-21 2010-04-29 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
JP2012508228A (ja) * 2008-11-07 2012-04-05 サムヤン コーポレイション メチルフェニデートの放出制御用薬剤学的組成物
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
CA2936740C (en) * 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder

Also Published As

Publication number Publication date
PL3261625T3 (pl) 2025-01-07
WO2016138440A1 (en) 2016-09-01
IL254159A0 (en) 2017-10-31
KR20170134409A (ko) 2017-12-06
DK3261625T3 (da) 2024-11-11
EP3261625A1 (en) 2018-01-03
HRP20241548T1 (hr) 2025-01-31
EP3261625B1 (en) 2024-08-14
LT3261625T (lt) 2024-12-10
CA2977540C (en) 2023-10-03
US20250049722A1 (en) 2025-02-13
ES2998038T3 (en) 2025-02-18
EP3261625A4 (en) 2018-10-24
AU2016225052A1 (en) 2017-09-21
US20180185290A1 (en) 2018-07-05
HUE068990T2 (hu) 2025-02-28
JP2021001190A (ja) 2021-01-07
US20160250148A1 (en) 2016-09-01
IL254159B (en) 2022-10-01
AU2021245179B2 (en) 2024-03-07
US20200146991A1 (en) 2020-05-14
SI3261625T1 (sl) 2025-03-31
JP2018506590A (ja) 2018-03-08
CA2977540A1 (en) 2016-09-01
BR112017018322A2 (pt) 2018-04-17
SMT202400479T1 (it) 2025-01-14
AU2021245179A1 (en) 2021-11-04
KR20240001281A (ko) 2024-01-03
AU2016225052B2 (en) 2021-07-08
FI3261625T3 (fi) 2024-11-13
IL254159B2 (en) 2023-02-01
RS66154B1 (sr) 2024-12-31
HK1248102A1 (en) 2018-10-12
US20230121531A1 (en) 2023-04-20
MX2017011005A (es) 2018-01-16
CN107530289A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
IL265609A (en) New formulations
IL254132A0 (en) Solid preparation
GB201607918D0 (en) Novel formulations
GB201516554D0 (en) Controlled-release formulations
HUE070183T2 (hu) Szilárd formuláció
GB201419091D0 (en) Formulations
ZA201704263B (en) Controlled-release formulations
GB201419261D0 (en) Formulations
IL275735A (en) Olanzapine sustained release pharmaceutical preparation
IL254159B (en) Stimulant formulations with triple release
IL252955B (en) Compounds for mouthwash
GB201520724D0 (en) Veterinary formulations
GB201805338D0 (en) Cosmetic formulations
IL268195A (en) Solid fosmetpantothenate formulations
GB201621277D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201617866D0 (en) Novel formulations
ZA201703472B (en) Mouthrinse formulations
GB201616509D0 (en) Novel formulations
GB201504482D0 (en) Novel formulations
GB201501153D0 (en) Immunogenic formulations